HoldiPharma and Dawah Pharma form export-focused JV: Egyptian state-owned pharma manufacturer HoldiPharma inked an agreement with US-based Dawah Pharma to establish a joint venture aimed at producing and exporting meds and supplements to international markets, with a focus on North America and Europe, according to a cabinet statement. Dawah Pharma will hold a 60% stake in the new entity, and HoldiPharma will hold the remaining 40%.

The game plan: The first phase will see the JV manufacturing six nutritional supplements and exporting them to the US, marking HoldiPharma’s entry into the country. The company plans to produce a range of products including syrups, tablets, ampoules, dietary supplements, pre-filled syringes, sterile injectables, ophthalmic meds, and over-the-counter meds.

These products will be developed in line with the standards of top global regulators, including the US Food and Drug Administration and the European Medicines Agency. This will boost their competitiveness across different markets in North America, Europe, Africa, and Asia.

This comes hot on the heels of the US-Egypt Policy Leaders Forum, where senior officials signaled a new phase in bilateral economic cooperation, including a customs agreement that’s in its final stages.

The pharma sector is on a tear — and the new JV is riding the wave: Egypt’s pharma market expanded 41% y-o-y in value last year, driven largely by price hikes. With more increases on the way and a revamped pricing framework in the works, analysts are penciling in another 25% market growth in 2025.

Tags: